A consolidated list of all the FDA approved medications during the month of March 2026.

  • Neffy (epinephrine nasal spray) Expanded Indication 
    • Indication expanded to remove the age criteria so all children and adults who weigh 33 lbs. or more can utilize neffy for the emergency treatment of Type 1 allergic reactions, including anaphylaxis.
  • Kresladi (marnetegragene autotemcel)  
    • For the treatment of pediatric patients with severe leukocyte adhesion deficiency type 1 (LAD-1).
  • Avlayah (tividenofusp alfa-eknm)
    • For the treatment of neurologic manifestations of Hunter syndrome (mucopolysaccharidosis type II, or MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment.
  • Lifyorli (relacorilant)  
    • In combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
  • Opdivo (nivolumab) New Indication 
    • With doxorubicin, vinblastine, and dacarbazine (AVD) chemotherapy for the first-line treatment of patients aged 12 years and older with stage III or IV classic Hodgkin lymphoma.
  • Imcivree (setmelanotide) New Indication 
    • To treat acquired hypothalamic obesity (HO) in adults and pediatric patients aged 4 years and older.
  • Lynavoy (linerixibat) 
    • For the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis.
  • Wegovy HD (semaglutide) 
    • For weight loss and long-term maintenance of weight loss for certain adult patients.
  • Icotyde (icotrokinra)  
    • For the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy.
  • Cosentyx (secukinumab) Expanded Indication 
    • For patients 12 years and older with moderate to severe hidradenitis suppurativa (HS).
  • Arexvy (respiratory syncytial virus vaccine, [adjuvanted])) Expanded Indication 
    • Expanded to include adults aged 18 to 49 years at increased risk for lower respiratory tract disease (LRTD) caused by RSV.
  • Wellcovorin (leucovorin) New Indication 
    • For treatment of adults and children with cerebral folate deficiency and a confirmed variant in the folate receptor 1 gene (CFD-FOLR1), an ultra-rare brain disorder that can resemble autism.
  • Pylarify TruVu (piflufolastat F 18) New Formulation
    • For positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.
  • Sotyktu (deucravacitinib) New Indication 
    • For the treatment of adults with active psoriatic arthritis.
  • Tecvayli + Darzalex Faspro (teclistamab-cqyv + daratumumab and hyaluronidase-fihj) New Combination
    • For the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent.
  • Juxtapid (lomitapide) Expanded Indication
    • For the treatment of patients 2 years of age and older with homozygous familial hypercholesterolemia.

Make sure to sign up for alerts and stay informed on all the latest published guidelines, FDA decisions, and more!

Copyright © 2026 Guideline Central, All Rights Reserved.